Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates
XMT-1536 Phase 1 dose escalation data update selected for late-breaker oral presentation at upcoming Society of Gynecologic Oncology (SGO) 2020 […]